News

Recent News About Hesperos and Human-on-a-Chip Technology

In Memoriam: Jeffrey M. Anderson, PhD

By Hesperos | March 28, 2025 | Comments Off on In Memoriam: Jeffrey M. Anderson, PhD

In loving memory of Jeffrey M. Anderson February 16, 1957 – March 1, 2025 We are deeply saddened to announce the passing of Jeffrey M. Anderson, PhD. Dr. Anderson passed away on March 1, 2025, after … Read More

New Study with Vanda Pharmaceuticals Explores Personalized Treatment Development Using Human-on-a-Chip

By Hesperos | March 12, 2025 | Comments Off on New Study with Vanda Pharmaceuticals Explores Personalized Treatment Development Using Human-on-a-Chip

“[This] is a demonstration of how these novel technologies can be leveraged to develop a new treatment paradigm – moving away from the one-treatment-fits-all perspective and towards the development of personalized medicines,” Mihael H. Polymeropoulos, M.D., … Read More

Michael Shuler, PhD – Ask Me Anything: Body-On-A-Chip

By Hesperos | February 24, 2025 | Comments Off on Michael Shuler, PhD – Ask Me Anything: Body-On-A-Chip

Ask Me Anything: Body-On-A-Chip Michael Shuler, PhD was featured on Technology Network’s Ask Me Anything: Body-On-A-Chip webinar and answered questions from a live audience.  January 31, 2025: Hosted by Technology Networks, Hesperos President Michael Shuler, PhD, … Read More

Hesperos and UCF Researchers Develop Human-on-a-Chip® Platform to Address Opioid Crisis

By Hesperos | January 9, 2025 | Comments Off on Hesperos and UCF Researchers Develop Human-on-a-Chip® Platform to Address Opioid Crisis
Title of a scientific journal article that reads "Microphysiological system to address the opioid crisis: A novel multi-organ model of acute opioid overdose and recovery"

ORLANDO, FLORIDA – Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their research, published in Alzheimer’s and Dementia, aims to improve our understanding and treatment of the disease.

Researchers Develop Human iPSC-Derived Myelination Model, Enabling Investigation and Treatment Development for Incurable Peripheral Nervous System Diseases

By Hesperos | October 25, 2024 | Comments Off on Researchers Develop Human iPSC-Derived Myelination Model, Enabling Investigation and Treatment Development for Incurable Peripheral Nervous System Diseases

FOR IMMEDIATE RELEASE ORLANDO, FL – October 24, 2024 – Hesperos, a leader in human-on-a-chip technology, has announced a breakthrough with the development of a human induced pluripotent stem cell (iPSC)-derived model of peripheral myelination. Published … Read More

Hesperos Appoints Lawrence Florin as Chief Executive Officer

By Hesperos | October 22, 2024 | Comments Off on Hesperos Appoints Lawrence Florin as Chief Executive Officer

Hesperos Appoints L. Florin as CEO “I am excited to join Hesperos during this period of explosive growth […and] lead this exceptional team as we continue delivering breakthrough solutions that advance drug discovery and benefit patients … Read More

Hesperos Provides Support for an Investigational Product for a Phase II Clinical Trial with its Human-on-a-Chip®

By Hesperos | September 24, 2024 | Comments Off on Hesperos Provides Support for an Investigational Product for a Phase II Clinical Trial with its Human-on-a-Chip®

PRESS RELEASE: Hesperos announces its Human-on-a-Chip® technology supported Dianthus Therapeutics’ FDA submission for a Phase II trial of DNTH103 for generalized myasthenia gravis.